Chiusura precedente | 177,20 |
Aperto | 176,49 |
Denaro | 177,67 x 100 |
Lettera | 178,67 x 200 |
Min-Max giorno | 175,99 - 180,12 |
Intervallo di 52 settimane | 77,10 - 189,97 |
Volume | |
Media Volume | 397.650 |
Capitalizzazione | 5,034B |
Beta (5 anni mensile) | 0,86 |
Rapporto PE (ttm) | 456,23 |
EPS (ttm) | 0,39 |
Prossima data utili | 06 mag 2024 - 10 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 185,90 |
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Chardan 7th Annual Genetic Medicines Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conferenc
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for KB408 for the treatment of alpha-1 antitrypsin deficiency (A
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the c